Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 86,052 | 95,111 | 112,322 | 131,539 | 140,138 |
| TOTAL | $111,625 | $117,817 | $131,426 | $145,633 | $155,492 |
| Non-Current Assets | |||||
| PPE Net | 5,827 | 6,954 | 8,107 | 9,171 | 9,648 |
| Other Non-Current Assets | 5,224 | 6,415 | 6,208 | 6,652 | 10,198 |
| TOTAL | $11,051 | $13,369 | $14,315 | $15,823 | $19,846 |
| Total Assets | $122,676 | $131,186 | $145,741 | $161,456 | $175,338 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,248 | 2,865 | 3,313 | 5,629 | 5,352 |
| Accrued Expenses | 10,602 | 7,225 | 6,712 | 7,828 | 8,209 |
| TOTAL | $18,470 | $14,295 | $13,653 | $16,996 | $18,181 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,068 | 1,416 | 1,740 | 2,091 | 941 |
| TOTAL | $1,068 | $1,416 | $1,740 | $2,091 | $3,672 |
| Total Liabilities | $19,538 | $15,711 | $15,393 | $19,087 | $21,853 |
| Shareholders' Equity | |||||
| Common Shares | 54 | 54 | 54 | 54 | 54 |
| Retained earnings | -308,201 | -288,606 | -272,226 | -259,952 | -241,322 |
| Other shareholders' equity | -7,813 | -13,887 | -14,082 | -12,943 | -19,062 |
| TOTAL | $103,138 | $115,475 | $130,348 | $142,369 | $153,485 |
| Total Liabilities And Equity | $122,676 | $131,186 | $145,741 | $161,456 | $175,338 |